SAR3419 is in phase 1 trial for CD19+ NHL histological subtypes and it indicates encouraging activity in indolent and aggressive NHL with 33% error at the maximum-tolerated dose (MTD). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.